Related by context. All words. (Click for frequent words.) 72 preclinical studies 71 vitro studies 70 preclinical models 69 preclinical efficacy 69 OXi# 68 CGEN # 68 antitumor effects 68 preclinically 68 polymerase inhibitor 68 orally bioavailable 67 INGN 67 HCV protease 67 potent inhibitor 67 selective inhibition 67 histone deacetylase inhibitor 67 pan HDAC inhibitor 67 oral prodrug 67 CA4P 67 neuroprotective properties 66 favorable pharmacokinetic profile 66 ENMD # 66 potently inhibits 66 CCR2 66 antitumor 66 vitro experiments 66 fosbretabulin 66 HSP# inhibitor 66 Pharmacokinetic studies 66 antitumor activity 66 anti leukemic 66 APOPTONE 66 Hsp# Inhibitor 65 histone deacetylase HDAC inhibitor 65 selectively inhibits 65 potent antitumor activity 65 Factor VIIa 65 CDK inhibitor 65 anti angiogenic 65 xenograft models 65 Pharmacokinetics PK 65 entinostat 65 oral bioavailability 65 PI3K inhibitor 65 CORT # 65 IL #E 65 novel VDA molecule 65 immunomodulatory 65 pharmacodynamic properties 65 Immunohistochemical analysis 64 EZN 64 antiviral activity 64 Preclinical studies suggest 64 potent anti angiogenic 64 targeting CD# 64 Xanafide 64 GRNCM1 64 MEK inhibitor 64 depsipeptide 64 Omacetaxine mepesuccinate 64 S/GSK# 64 PXD# 64 novel peptide 64 huN# DM1 64 vascular disrupting agent 64 nonclinical studies 64 anti fibrotic 64 decitabine 64 orally administered inhibitor 64 milatuzumab 64 AKT inhibitor 64 anti angiogenic agent 64 vivo efficacy 64 mertansine 64 induce apoptosis 64 sorafenib Nexavar 64 multi kinase inhibitor 64 inhibitory effects 64 small molecule tyrosine 64 angiogenesis inhibitor 64 bendamustine 64 anticancer agent 64 proteasome inhibitor 64 ANAVEX #-# [001] 64 HGS ETR2 64 PSN# [002] 64 immunostimulatory 64 induces apoptosis 64 resolvin 63 BNC# 63 vascular disrupting agents 63 neurotrophic 63 tyrosine kinase inhibitor 63 Angiolix 63 GRN#L 63 HGS# 63 novel histone deacetylase 63 vascular disrupting 63 systemically administered 63 anticancer activity 63 virus HCV protease inhibitor 63 erlotinib Tarceva ® 63 syngeneic 63 intratumoral injection 63 plasma kallikrein inhibitor 63 Inosine 63 neuroprotective effects 63 PDE4 inhibitor 63 neuroprotective 63 potent inhibition 63 NOD SCID mice 63 Debio 63 antisense inhibition 63 potent anticancer 63 protein kinase inhibitor 63 xenografts 63 trastuzumab Herceptin R 63 antiangiogenic activity 63 CD# monoclonal antibody 63 pharmacodynamic profile 63 liposomal formulation 63 multikinase inhibitor 63 AMD# [003] 63 KSP inhibitors 63 Onconase 63 partial agonist 63 highly selective inhibitor 63 PCK# 63 antibody MT# 63 Vidofludimus 63 ocular formulation 63 olaparib 63 solithromycin 63 CYT# potent vascular disrupting 63 INCB# [001] 63 K ras mutations 63 vitro cytotoxicity 63 FK# 63 Azixa 63 Kahalalide F 63 chemotherapeutic drug 63 anti proliferative 62 PEG SN# 62 demonstrated antitumor activity 62 pegylated liposomal doxorubicin 62 vidofludimus 62 UsiRNAs 62 CCR9 62 HQK 62 antisense oligonucleotide 62 selective modulator 62 ACZ# 62 novel anticancer 62 cytoprotective 62 NS#/#A protease 62 immunomodulator 62 Seliciclib 62 investigational humanized monoclonal antibody 62 CBLC# 62 PKC# 62 small molecule defensin 62 mouse xenograft models 62 Pemetrexed 62 anti amnesic 62 Bortezomib 62 pro apoptotic 62 Preclinical 62 immune modulatory 62 AAG geldanamycin analog 62 mapatumumab 62 VEGF receptor 62 Phase Ib clinical 62 PRT# 62 #ME# 62 XL# inhibits 62 JAK2 inhibitor 62 DXL# 62 Tyrima 62 PD LID 62 alvespimycin 62 PEGylated anti 62 viral kinetics 62 tolerability profile 62 Sphingomab 62 BAL# [001] 62 adenoviral 62 Aurora kinase 62 MET amplification 62 IAP inhibitor 62 Gleevec resistant 62 effector function 62 OMP #M# 62 sunitinib Sutent ® 62 kinase inhibitor 62 taxane resistant 62 Kevetrin 62 receptor agonist 62 selective inhibitor 62 TG# [003] 62 cMET 62 CCX# 62 Panzem 61 ProSavin 61 GAP #B# 61 antitumor efficacy 61 flavopiridol 61 humanized anti 61 small molecule inhibitor 61 retapamulin 61 Aplidin 61 Sym# 61 Azedra 61 Homspera 61 HuMax CD# 61 TRAIL induced apoptosis 61 small molecule inhibitors 61 Enzastaurin 61 ganetespib 61 interferon IFN 61 inhibit tumor 61 Carfilzomib 61 MGd 61 nucleoside analog 61 potently inhibited 61 pharmacodynamic PD 61 prodrug 61 vivo 61 MT# MEDI 61 JAK1 61 dasatinib Sprycel 61 calcitonin 61 VEGFR2 61 bortezomib Velcade 61 antiviral potency 61 Pentraxin 2 61 immunomodulating 61 selective agonist 61 receptor tyrosine kinase inhibitor 61 mTOR inhibitors 61 neuroprotectant 61 cannabinor 61 Zoraxel 61 reversible inhibitor 61 receptor blocker 61 GHRH 61 antifibrotic 61 inhibitor RG# 61 SCH # 61 Valortim 61 preclinical 61 cetuximab Erbitux R 61 Fc fusion protein 61 VA# [002] 61 JAK inhibitors 61 Posiphen 61 ON #.Na 61 PEGPH# 61 HGS ETR1 61 beta 1a 61 Omacetaxine 61 GLYX 61 imatinib Gleevec ® 61 Irinotecan 61 Interferon alpha 61 JAK inhibitor 61 urocortin 2 61 receptor inhibitor 61 TLR8 61 RGB # 61 HDACi 61 secretory phospholipase A2 sPLA2 61 Archexin 61 phase IIb clinical 61 Anticalin ® 61 Palifosfamide 61 synthetic peptide 61 MYDICAR ® 61 selective kinase inhibitor 61 alagebrium 61 orally dosed 61 PEGylated Fab fragment 61 human tumor xenografts 61 imetelstat 61 Tezampanel 61 XL# anticancer compounds 61 TTR gene 61 xenograft model 61 bevacizumab Avastin ® 61 HDAC inhibitor 61 KSP inhibitor 61 pharmacokinetic properties 61 bortezomib Velcade ® 61 pharmacokinetic profile 61 MAGE A3 ASCI 61 TRO# 61 Preclinical Study 61 selective antagonist 61 inhibited tumor 61 Golimumab 61 Aflibercept 61 Symadex 61 omega interferon 61 HuMax EGFr 61 vivo validation 61 selective androgen receptor modulator 61 LB# [003] 61 vorinostat 61 TLR9 agonist 61 somatostatin analogue 61 IGF 1R inhibitor 61 cardioprotective effects 61 Ceflatonin 61 inhibitor VX 61 NexACT 61 BRAF inhibitor 61 XmAb# 61 DDP# 61 axitinib 61 Kinase Inhibitor 61 administered subcutaneously 61 YONDELIS 61 riociguat 61 AQ4N 61 Cloretazine 61 gemcitabine Gemzar ® 61 Aurora kinase inhibitor 61 mGluR2 NAM 61 Synavive 60 Guanilib 60 Thiarabine 60 GRN# 60 GLP toxicology studies 60 GMX# 60 sunitinib Sutent 60 E#F# 60 5 HT6 receptor 60 antiproliferative activity 60 HIF PH inhibitors 60 A3 adenosine receptor 60 bleomycin 60 antidepressant efficacy 60 Anticalin R 60 pharmacokinetic studies 60 Panzem R 60 iroxanadine 60 Ocrelizumab 60 EpCAM 60 Traficet EN 60 PLX cells 60 generation nucleoside analog 60 immune modulation 60 cytotoxicity 60 TLR7 60 Imprime PGG 60 lumiliximab 60 NeuroVax TM 60 SYN# 60 inhibitory activity 60 HuLuc# 60 TNFα 60 Apoptone 60 CaPre TM 60 Tarvacin TM 60 TREANDA 60 alkylating agent 60 geldanamycin 60 TNFalpha 60 exon skipping 60 PS# [001] 60 antiangiogenic 60 poly ADP ribose polymerase 60 etoposide 60 JVRS 60 Triolex 60 enzyme inhibitor 60 sphingosine 1 60 generation Hsp# inhibitor 60 EndoTAG TM -1 60 TELINTRA 60 mu opioid receptor antagonist 60 murine model 60 tafamidis 60 huC# DM4 60 immunomodulatory effects 60 sulodexide 60 PEG IFN 60 2 inhibitor CYT# 60 estrogen receptor beta 60 Phase Ib study 60 ATL# [001] 60 miR #a [001] 60 anti CD3 60 Tanespimycin 60 Amplimexon 60 HER3 60 Telintra 60 NEUGENE 60 CD# CEA 60 dasatinib Sprycel ® 60 Cannabinor 60 rBChE 60 pathophysiological effects 60 IFN α 60 colon carcinoma 60 phase 2a 60 CYC# 60 PARP inhibitor 60 brivaracetam 60 Solorel TM 60 INCB# [003] 60 siRNA therapeutic 60 safinamide 60 mitogen activated ERK kinase 60 SERMs 60 CCR5 antagonist 60 DAVANAT 60 neurologic progression 60 PDGFR 60 Granulocyte Colony Stimulating Factor 60 ASONEP 60 gamma secretase inhibitor 60 tumor xenograft models 60 mineralocorticoid receptor 60 trodusquemine 60 antiapoptotic 60 Safinamide 60 Presents Preclinical Data 60 pharmacokinetics PK 60 anti phosphatidylserine 60 PSMA ADC 60 Orally administered 60 antisense drug 60 HuMax CD4 60 inosine 60 receptor antagonist 60 potent antiviral 60 MORAb 60 androgen independent 60 TNFa 60 vivo preclinical studies 60 humanized monoclonal antibodies 60 mecamylamine 60 G CSF 60 Valortim ® 60 TRX1 60 meropenem 60 Catena ® 60 pegylated 60 thalidomide Thalomid 60 peptide conjugated 60 antidiabetic 60 ImmunoVEX HSV2 60 Overexpression 60 vinca alkaloid 60 proto oncogene 60 LSI #P 60 GW# [003] 60 pDCs 60 ADP receptor antagonist 60 chimeric monoclonal antibody 60 HGS ETR1 mapatumumab 60 lenalidomide dexamethasone 60 FGFR 60 experimental autoimmune encephalomyelitis 60 Tamibarotene 60 HDAC Inhibitor 60 PNP inhibitor 60 antiproliferative effects 59 favorable tolerability 59 thrombin receptor 59 neuroregenerative 59 ERK1 2 59 Phase Ib clinical trials 59 Phase 1b trial 59 chemokine receptor 59 SRT# [003] 59 Phase 2a clinical 59 isoform selective 59 Vandetanib 59 upregulation 59 potently inhibit 59 davunetide intranasal AL 59 generation antisense inhibitor 59 pertuzumab 59 VELCADE melphalan 59 Tesmilifene 59 multiple myeloma MM 59 Ventavis ® 59 fusion protein 59 statistically significant efficacy 59 Romidepsin 59 PRTX 59 RH1 59 antisense inhibitor 59 non nucleoside inhibitor 59 Androxal TM 59 xenograft 59 DNA intercalator 59 phosphate S1P 59 stable nucleic acid 59 factor G CSF 59 PEG Interferon lambda 59 selectively inhibited 59 SGS# 59 evaluating tivozanib 59 alpha folate receptor 59 muscarinic 59 RAV# 59 adult mesenchymal stem 59 AEG# 59 romidepsin 59 oral FTY# 59 cytostatic 59 intranasal formulation 59 amrubicin 59 HCV protease inhibitor 59 vaccine GRNVAC1 59 MAb 59 sodium glucose cotransporter 59 immune modulating 59 TRIOLEX 59 KB# [002] 59 Subgroup analysis 59 Prodarsan ® 59 vivo preclinical 59 antiangiogenic agent 59 pharmacokinetic PK study 59 immunotoxin 59 cytokine refractory 59 Pharmacokinetic analyzes 59 matrix metalloproteases 59 elotuzumab 59 Perifosine 59 mGluR5 negative 59 midstage trials 59 peripherally acting 59 Vorinostat 59 highly immunogenic 59 Th1 type 59 JAK2 59 murine 59 induced apoptosis 59 GRNVAC1 59 BEZ# 59 Valortim R 59 peptide antigens 59 MEK inhibitors 59 c MYC 59 PEGylated 59 masitinib 59 selective inhibitors 59 AZD# 59 Zybrestat 59 mediated inhibition 59 CRLX# 59 Epratuzumab 59 eltrombopag 59 Ceflatonin R 59 THR beta agonist 59 RNAi mediated 59 gemcitabine Gemzar 59 bevacizumab Avastin R 59 EGFR HER2 59 oral JAK1 59 zileuton 59 trastuzumab Herceptin ® 59 pharmacodynamic markers 59 Iloperidone 59 INC# 59 tumorigenicity 59 RNA antagonist 59 Janus kinase 59 targeted antifolate 59 Pharmacokinetic PK 59 immune stimulatory 59 NGX# 59 D aspartate NMDA receptor 59 AEGR 59 Doxil ® 59 tumor vasculature 59 IAP inhibitors 59 microglial activation 59 glucagon receptor 59 metastatic malignant 59 novel synthetic peptide 59 Erlotinib 59 teriflunomide 59 SNT MC# 59 crizotinib PF # 59 investigational protease inhibitor 59 forskolin 59 Nanobody 59 CTAP# Capsules 59 hypoxia inducible factor 59 imatinib therapy 59 Cethromycin 59 PTHrP 59 acetonide FA 59 IgG1 antibody 59 Rasagiline 59 pro angiogenic 59 receptor antagonists 59 tumor antigen 59 FOLFOX6 59 dexamethasone Decadron 59 siRNA mediated 59 CYT# 59 IMA# 59 Hedgehog signaling pathway 59 AVN# [001] 59 XL# XL# 59 p# MAP kinase inhibitor 59 LY# [003] 59 protein tyrosine phosphatase 1B 59 Cytochrome P# 59 vapreotide acetate 59 Bendamustine 59 FGFR2 59 CD# antibody [001] 59 phase IIb study 59 tubulin polymerization 59 TOCOSOL Paclitaxel 59 phase IIa clinical 59 small molecule agonists 59 P2Y 59 Phase 2a trial 59 plasma pharmacokinetics 59 GSK # 59 gemcitabine 59 Aplidin R 59 OncoVEX GM CSF 59 humanized monoclonal antibody 59 TKM ApoB 59 Everolimus 59 Meets Primary Endpoint 59 LT NS# 59 CG# [003] 59 PegIFN 59 antitumour activity 59 IRX 2 59 VQD 59 dexpramipexole 59 RhuDex ® 59 TNF α 59 CERE 59 antithrombotic 59 telomerase inhibitor drug 59 tumor vascular disrupting 59 Eg5 59 MAPK pathway 59 Radilex 59 nab paclitaxel 59 SIRT1 activators 59 inhibitory effect 59 docetaxel Taxotere ® 59 dose dependently 59 LRAT 59 BiTE antibodies 59 MT#/MEDI-# 59 monoclonal antibody mAb 59 VAPRISOL 59 GDIR 59 RANKL 59 subcutaneously administered 59 pharmacodynamic 59 thymalfasin 59 radiation sensitizer 59 demethylating agents 59 CIMZIA ™ 59 5 HT4 receptor 59 pomalidomide 59 potent inhibitors 59 mGlu2 3 59 PPARgamma 59 Multimeric 59 PDE1 59 polycythemia vera PV 59 HIF PHI 59 HIF 1α 59 2 methoxyestradiol 59 tipifarnib 59 JAK2 inhibitors 59 cetuximab Erbitux ® 59 PI3K Akt 59 estramustine 59 ESBA# 59 JAK3 59 proteasome inhibitors 59 splice variants 58 antitumor effect 58 leukemia AML 58 promoter methylation 58 bexarotene 58 FUS1 58 KRN# 58 TRAIL R2 58 rFIXFc 58 Cloretazine R VNP#M 58 REP# 58 tiapamil 58 ALN TTR# 58 ANG# 58 pharmacokinetic equivalence 58 RG# [001] 58 MET VEGFR2 58 Cloretazine ® 58 ATL/TV# 58 pharmacological chaperone 58 OvaRex R 58 Bendavia 58 alpha antagonist 58 cis retinoic acid 58 HCD# [002] 58 virus AAV 58 IL 1ß 58 #beta HSD1 58 brostallicin 58 Liposomal 58 PPARγ 58 oncolytic virus 58 LHRH antagonists 58 Belerofon 58 CCR9 antagonist 58 tezampanel 58 tolerability 58 mGluR5 NAM 58 CTLA 4 58 partial agonists 58 XL# XL# XL# 58 bortezomib 58 db db mice 58 R roscovitine 58 DFMO 58 potent antiproliferative 58 Phase 1b clinical trials 58 phase IIa 58 mTOR inhibition 58 ligand TRAIL 58 Bavituximab 58 vivo potency 58 imatinib Gleevec 58 baminercept 58 Akt activation 58 IGF 1R 58 Aliskiren 58 gefitinib Iressa 58 irreversible inhibitor 58 weekly subcutaneous injections 58 GM CSF 58 hepatoma 58 INT# [002] 58 Afatinib 58 Calcitonin 58 #D#C# 58 OMP #R# 58 androgen receptor AR 58 OMNARIS HFA 58 Bruton tyrosine kinase 58 ARIKACE ™ 58 tumor specific antigen 58 5FU 58 radiolabeled monoclonal antibody 58 LY# [002] 58 DepoVax 58 anticancer compound 58 triphendiol 58 hematological cancers 58 YONDELIS R 58 fluticasone furoate 58 EDEMA3 trial 58 varespladib 58 HspE7 58 factor Xa inhibitor 58 Epothilones 58 nebulized formoterol fumarate 58 Gefitinib 58 Phase 1a clinical 58 Enkephalin 58 p# mitogen activated 58 Virulizin ® 58 mTOR inhibitor 58 ZOLINZA 58 fluvastatin 58 trastuzumab Herceptin 58 receptor partial agonist 58 RRM1 58 biodistribution 58 Exherin TM 58 Etoposide 58 DP b# 58 GPR# [002] 58 SNALP technology 58 eniluracil 58 ZFN modified 58 monoclonal 58 defensin mimetic antibiotic 58 nicotinic alpha 7 58 oral Hsp# inhibitor 58 PTP 1B 58 diabetic neuropathic pain 58 paricalcitol 58 BioVant 58 IIa trial 58 aurora kinase inhibitor 58 humanized monoclonal 58 trabectedin 58 Phase #b/#a clinical 58 menadione 58 metastatic castration resistant 58 histone deacetylase inhibitors 58 alfa 2a 58 tiotropium bromide 58 p# activation 58 bicalutamide 58 PSN# [001] 58 transgenic mouse model 58 Tarvacin 58 antiproliferative 58 intracoronary 58 radiolabeled 58 intravenously administered 58 adecatumumab 58 RDEA# 58 pharmacodynamic profiles 58 Glufosfamide 58 metaglidasen 58 HMG CoA reductase inhibitors 58 Cathepsin B 58 Tumor Necrosis Factor 58 bactericidal activity 58 Lenocta 58 Plicera 58 HCV protease inhibitors 58 investigational oral hepatitis C 58 antagomirs 58 RhuDex R 58 neuropilin 58 TLR agonists 58 SARMs 58 seliciclib 58 labetuzumab 58 CEQ# 58 activin 58 HIF 1alpha 58 plasma kallikrein 58 vimentin 58 EOquin TM 58 TMC# [002] 58 indibulin 58 murine monoclonal antibody 58 TMC# C# 58 AVE# 58 N methyl 58 T#I [002] 58 mda 7 58 p# inhibitor 58 Serdaxin 58 inhibits tumor 58 Panzem R NCD 58 iSONEP 58 NRG1 58 selectively binds 58 CTGF 58 anticancer 58 MultiStem 58 MTP inhibitor 58 Azacitidine 58 immunofluorescence staining 58 davunetide 58 endostatin 58 BiTE antibody 58 serine protease 58 Antiangiogenic 58 somatostatin 58 HCV replicon 58 mTOR mammalian target 58 Janus Kinase 58 agonist 58 cilengitide 58 Abl 58 Tolvaptan 58 receptor monoclonal antibody 58 acetylcholinesterase 58 investigational compound 58 receptor agonists 58 Alagebrium 58 obatoclax 58 Laquinimod 58 Phase #b/#a trial 58 neratinib 58 Akt inhibitor 58 refractory chronic lymphocytic 58 DACH platinum 58 IFN alpha 58 ruxolitinib 58 IMGN# 58 Voreloxin 58 PTP1B 58 survivin 58 Vitaxin 58 telaprevir dosed 58 sorafenib tablets 58 Annexin V 58 Dasatinib 58 triterpenoids 58 naturally occurring molecule 58 Notch1 58 Darinaparsin 58 docetaxel Taxotere 58 DiLA2 liposomes 58 HDAC inhibitors 58 small molecule activator 58 BMS # 58 antiarrhythmic 58 Gemcitabine 58 Rebif ® 58 cytotoxin 58 ^ sup #m 58 gemcitabine carboplatin 58 mitogen activated protein kinase 58 CLORETAZINE TM VNP#M 58 neuroprotection 58 volociximab 58 histone deacetylase HDAC 58 tyrosine kinase receptor 58 TGF beta1 58 neurotrophic factor 58 leukemia CLL 58 Hedgehog pathway 58 UPLYSO 58 Ophena TM 58 transgenic mouse models 58 Copegus ribavirin 58 microRNA miR 58 calcitriol 58 gemcitabine cisplatin 58 TLK# 58 aurora kinase 58 Personalized Immunotherapy 58 CDK inhibitors 58 PGE2 58 TYKERB 58 EGF receptor 58 receptor antagonism 58 ghrelin receptor 58 TKM PLK1 58 TLR9 58 NEUGENE antisense 58 cytotoxic 58 DermaVir 58 Lisofylline 58 anti EGFR antibody 58 Tie2 58 AP# [003] 58 paclitaxel Taxol 58 IFN Beta 58 alkylating agents 58 antisense inhibitors 58 siRNAs targeting 58 active metabolite 58 lenalidomide Revlimid R 57 cyclin dependent kinase CDK 57 SOCS3 57 anti CD3 antibody 57 CIMZIA TM 57 glycogen synthase kinase 57 peptidic compound 57 Cloretazine R 57 Blinatumomab 57 talabostat 57 CRF1 receptor antagonist 57 ErbB3 57 lysosomal 57 EGS# 57 Curaxin CBLC# 57 potent inhibitory 57 Phase IIa trial 57 antiviral efficacy 57 favorable pharmacokinetic 57 neurotoxicity 57 annexin 57 5 HT1A 57 ZYBRESTAT fosbretabulin 57 mediated apoptosis 57 cell lymphoma CTCL 57 orthotopic model 57 humanized antibody 57 5 fluorouracil 57 KL4 surfactant 57 Parkinson disease levodopa induced 57 adipogenic 57 otelixizumab 57 alpha#beta# integrin 57 ELACYT 57 NMDA antagonist 57 ZYBRESTAT 57 Alocrest 57 Anticalin 57 Phase IIb trials 57 Anthim